DCC4646 |
Sch-43478 |
Non-nucleoside antiviral agent, having potent and selective activity against herpes simplex virus type 2 (HSV-2) |
|
DCC4647 |
Sch-51866 |
Potent and selective PDE1 and PDE5 inhibitor |
|
DCC4648 |
Sch-538415 |
Novel Acyl_carrier_protein_synthase>acyl carrier protein synthase inhibitor; Inhibitor of growth of the bacteria Streptococcus_pneumoniae>Streptococcus pneumoniae and Neisseria_gonorrhoeae>Neisseria gonorrhoeae |
|
DCC4649 |
Sch-53870 |
Inhibitor of p21-hRas nucleotide exchange in vitro |
|
DCC4650 |
sch-79687 |
Novel histamine H3-receptor antagonist |
|
DCC4651 |
Sch-900822 |
Novel potent and selective glucagon receptor antagonist |
|
DCC4652 |
Schembl12616233 |
Novel inhibitor of SARS-CoV-2 main protease (MPro) |
|
DCC4653 |
Schembl1548848 |
Novel inhibitor of vanilloid receptor subtype 1 (VR1) |
|
DCC4654 |
Schembl15939407 |
Novel Lysine-Specific Demethylase 1 (LSD1) Inhibitor (IC50: 20nM) |
|
DCC4655 |
Schembl18320671 |
Novel glucose transport inhibitor |
|
DCC4656 |
Schembl18616095 |
Novel inhibitor of SARS-CoV-2 main protease (MPro) |
|
DCC4657 |
Schembl20148701 |
Novel inhibitor of SARS-CoV-2 main protease (MPro) |
|
DCC4658 |
scio-469 Hydrochloride |
Selective, ATP-competitive p38 |
|
DCC4659 |
Scq-14d |
Novel Inhibitor of p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs) with the IC50 values of 140, 910 and 17.5 nmol/L against MDM2, HDAC1, and HDAC6, respectively, showing the tumor growth inhibition (TGI) in the A549 xenograf |
|
DCC4660 |
Scr1693 |
Novel dual acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) |
|
DCC4661 |
Scr-4026 |
Novel inhibitor of nNOS-PSD-95 interaction, exhibiting neuroprotective activities in NMDA-induced or Oxygen and glucose deprivation (OGD)-induced neuronal damage in primary cortical neurons cultures, and ameliorating focal cerebral ischemic damage in rats |
|
DCC4662 |
Scriptene |
NRTI-drug pair of zidovudine (AZT)-didanosine (ddI), being highly cytotoxic and mutagenic |
|
DCC4663 |
S-cw3554 |
Novel irriversible selective PDI inhibitor, selectively labeling protein disulfide isomerase and inhibiting its enzymatic activity, showing unique cytotoxicity in cells derived from multiple myeloma |
|
DCC4664 |
Sd2590 Hydrochloride |
Potent inhibitor of MMP-2, -3, -9, -8, -13, and -14 |
|
DCC4665 |
Sdz 205-557 Hydrochloride |
Selective, surmountable antagonist for 5-HT4 receptors |
|
DCC4666 |
Sdz 90-215 |
Novel inhibitor of the Golgi complex (Vrg4); Antifungal |
|
DCC4667 |
Sdz Mrl 953 |
Novel immunostimulatory monosaccharidic lipid A analog, down-regulating TNF-alpha and IL-6 production and priming secretion of G-CSF and IL-1 beta |
|
DCC4668 |
Sdz Ser 082 Fumarate |
Selective 5-HT2B/2C receptor antagonist |
|
DCC4669 |
sdz-285604 |
Novel inhibitor of sterol 14a-demethylases (CYP51) |
|
DCC4670 |
Sdz-lap-977 |
Potent antiproliferative agent, binding to the “colchicine binding site” on tubulin and inhibiting tubulin polymerization in vitro |
|
DCC4671 |
sdz-nkt343 |
Highly selective human tachykinin NK1 receptor antagonist |
|
DCC4672 |
Secologanate |
Natural plant growth inhibitor |
|
DCC4673 |
Seco-rapamycin Ethyl Ester |
Novel open-ring metabolite of rapamycin derivative |
|
DCC4674 |
Securinine Mononitrate |
Antagonist of gamma-aminobutyric acid A (GABA A ) receptor and cholinergic agent |
|
DCC4675 |
Seh/ache Inhibitor 12c |
Novel Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease |
|